Funding for this research was provided by:
Alzheimer Society (AS-PG-2013-017)
Received: 18 November 2019
Accepted: 16 July 2020
First Online: 31 July 2020
Ethics approval and consent to participate
: Written consent was obtained for participation in the CFAS study. Ethical approval was obtained locally at all sites from 1991 and at Multi-centre research ethics committees <i>(CFAS I: REC99/5/22, 05/MRE05/37; CFAS II: 07/MRE05/48)</i> during the course of the study. For example, the first multi-centre ethical approval was obtained at the Anglia and Oxford multi-centre research ethics committee – part of the NHS REC (ref: 99/5/22). We requested the data from the CFAS National Coordinator. Data applications were reviewed by the Co-operative Management Committee (CMC) of CFAS. Datasets were created and released by CFAS Data Managers.Further detail on all ethical approvals can be found at: ExternalRef removed.Written informed consent was obtained from every participant. If the potential participant was considered to lack mental capacity, as per the Mental Capacity Act in the UK, assent was obtained from a key informant, usually a close family member. This method of consent was approved by an ethics committee.
: Not applicable.
: Prof. Fox and Dr. Maidment received travel grants and Profs Fox and Myint received lecture fees from Astellas Pharma UK. Prof. Loke received consultancy fees from Thame Pharmaceuticals. All other authors report no conflict of interest.